Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Ocugen (NASDAQ: OCGN), a biotechnology company specializing in gene and cell therapies, biologics, and vaccines, has scheduled a conference call and live webcast for Wednesday, March 5, 2025, at 8:30 a.m. ET. The event will cover the company's fourth quarter and full year 2024 financial results along with business updates.
The company will release its earnings announcement before the market opens on the same day. Investors can join via phone using the toll-free number (800) 715-9871 for U.S. callers or (646) 307-1963 for international participants, with Conference ID 5045393. A webcast will be available on Ocugen's investor site, with a replay accessible for approximately 45 days after the event.
Ocugen (NASDAQ: OCGN), un'azienda biotecnologica specializzata in terapie geniche e cellulari, biologici e vaccini, ha programmato una conferenza telefonica e una diretta web per mercoledì 5 marzo 2025, alle 8:30 ET. L'evento tratterà i risultati finanziari del quarto trimestre e dell'intero anno 2024 insieme agli aggiornamenti aziendali.
L'azienda pubblicherà l'annuncio degli utili prima dell'apertura del mercato nello stesso giorno. Gli investitori possono partecipare telefonicamente utilizzando il numero verde (800) 715-9871 per i chiamanti statunitensi o (646) 307-1963 per i partecipanti internazionali, con ID Conferenza 5045393. Una diretta sarà disponibile sul sito degli investitori di Ocugen, con una registrazione accessibile per circa 45 giorni dopo l'evento.
Ocugen (NASDAQ: OCGN), una empresa biotecnológica especializada en terapias génicas y celulares, biológicos y vacunas, ha programado una conferencia telefónica y una transmisión en vivo para el miércoles 5 de marzo de 2025, a las 8:30 a.m. ET. El evento cubrirá los resultados financieros del cuarto trimestre y del año completo 2024 junto con actualizaciones comerciales.
La empresa publicará su anuncio de ganancias antes de la apertura del mercado el mismo día. Los inversores pueden unirse por teléfono utilizando el número gratuito (800) 715-9871 para los llamantes de EE. UU. o (646) 307-1963 para los participantes internacionales, con ID de conferencia 5045393. Una transmisión estará disponible en el sitio de inversores de Ocugen, con una repetición accesible durante aproximadamente 45 días después del evento.
Ocugen (NASDAQ: OCGN), 유전자 및 세포 치료, 생물학적 제제 및 백신을 전문으로 하는 생명공학 회사가 2025년 3월 5일 수요일 오전 8시 30분 ET에 전화 회의 및 라이브 웹캐스트를 예정하고 있습니다. 이 이벤트에서는 2024년 4분기 및 전체 연도 재무 결과와 함께 비즈니스 업데이트가 포함됩니다.
회사는 같은 날 시장 개장 전에 수익 발표를 할 예정입니다. 투자자들은 미국 전화 사용자용 무료 전화번호 (800) 715-9871 또는 국제 참가자용 (646) 307-1963을 사용하여 참여할 수 있으며, 회의 ID는 5045393입니다. Ocugen의 투자자 사이트에서 웹캐스트를 이용할 수 있으며, 이벤트 이후 약 45일 동안 재생이 가능합니다.
Ocugen (NASDAQ: OCGN), une entreprise de biotechnologie spécialisée dans les thérapies géniques et cellulaires, les biologiques et les vaccins, a programmé une conférence téléphonique et un webinaire en direct pour mercredi 5 mars 2025, à 8h30 ET. L'événement couvrira les résultats financiers du quatrième trimestre et de l'année 2024 ainsi que des mises à jour sur les activités.
L'entreprise publiera son annonce de résultats avant l'ouverture du marché le même jour. Les investisseurs peuvent se joindre par téléphone en utilisant le numéro gratuit (800) 715-9871 pour les appelants américains ou (646) 307-1963 pour les participants internationaux, avec l'ID de conférence 5045393. Un webinaire sera disponible sur le site des investisseurs d'Ocugen, avec un replay accessible pendant environ 45 jours après l'événement.
Ocugen (NASDAQ: OCGN), ein Biotechnologieunternehmen, das sich auf Gen- und Zelltherapien, Biologika und Impfstoffe spezialisiert hat, hat eine Telefonkonferenz und einen Live-Webcast für Mittwoch, den 5. März 2025, um 8:30 Uhr ET angesetzt. Die Veranstaltung wird die Finanzergebnisse des vierten Quartals und des gesamten Jahres 2024 sowie Unternehmensupdates behandeln.
Das Unternehmen wird seine Gewinnankündigung vor der Markteröffnung am selben Tag veröffentlichen. Investoren können sich telefonisch unter der gebührenfreien Nummer (800) 715-9871 für Anrufer aus den USA oder (646) 307-1963 für internationale Teilnehmer mit der Konferenz-ID 5045393 einwählen. Ein Webcast wird auf der Investorenseite von Ocugen verfügbar sein, mit einer Wiederholung, die etwa 45 Tage nach der Veranstaltung zugänglich ist.
- None.
- None.
MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company’s fourth quarter and full year 2024 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 5, 2025.
Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details:
Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers
Conference ID: 5045393
Webcast: Available on the events section of the Ocugen investor site.
A replay of the call and archived webcast will be available for approximately 45 days following the event on the Ocugen investor site.
About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com
FAQ
When will Ocugen (OCGN) report Q4 and full year 2024 earnings?
How can investors access OCGN's Q4 2024 earnings call?
How long will OCGN's Q4 2024 earnings call replay be available?
What time is OCGN's Q4 2024 earnings conference call?
